Media.Player

Platelet Aggregation Inhibitors (P2Y 12-receptor antagonists)

总结

Platelet aggregation inhibitors: Novel antagonists of the P2Y12-receptor with antithrombotic effect.

技术优势

Innovative group of compounds for a validated target
No bioactivation for faster onset of action
Reversible binding to the receptor
Small molecules for inexpensive production process

技术应用

Drug discovery, Modulation of P2 receptors in platelets is of paramount importance in regulating platelet function, and, as a consequence, in controlling thrombotic diseases,

详细技术说明

The P2Y12-receptor on blood platelets is the target of known antithrombotic drugs (e.g. clopidogrel). The receptor is therefore validated for this therapeutic use. Furthermore, the P2Y12-receptor is expressed in certain parts of the brain, which opens new routes for the treatment of neuroinflammatory and neurodegenerative diseases. This invention provides novel antagonists of the P2Y12-receptor. The disclosed novel compounds show reversible and selective binding to the P2Y12-receptor. The molecules do not require bioactivation.

合作类型

Licensing

申请日期

07/03/2008 00:00:00

申请号码

EP20080735068 20080307

分类

- international:
A61K31/136; A61P7/02; A61P9/10; C07C229/74; C07C309/46; C07C309/53; C07C323/37; C07D239/42; C07D251/42; C07D251/44; C07D251/46; C07D251/50
- cooperative:
C07C229/74; C07C309/46; C07C309/53; C07C323/37; C07D251/42; C07D251/44; C07D251/46; C07D251/50; C07C2603/24

其他

Patent application

ID号码

1526

国家/地区

德国